ZILRETTA
Peaktriamcinolone acetonide extended-release injectable suspension
NDAINTRA-ARTICULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 5h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZILRETTA is an extended-release intra-articular injection of triamcinolone acetonide, a corticosteroid designed to provide sustained anti-inflammatory effects directly within the joint. It is indicated for intra-articular use to manage osteoarthritis pain and inflammation. The extended-release formulation allows for prolonged therapeutic duration compared to standard intra-articular corticosteroid injections.
$0.01BPart D
Peak4.9 years to LOEProduct is at peak lifecycle with modest Medicare spending but faces significant competitive pressure, suggesting a stable but challenged commercial environment requiring focused sales execution.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.